Prague Med. Rep. 2025, 126, 121-138
https://doi.org/10.14712/23362936.2025.20
Development, Implementation, Pharmacokinetic and Safety Evaluation of an Immunotherapeutic Treatment for COVID-19: Double-blind Randomized Placebo-controlled Trial
Guillermo Alberto Keller1,2,3
, Silvia Miranda3, Adolfo Rafael De Roodt1, Roxana Salvi2, Ivana Colaianni2, Elizabeth García2, Guillermo Bramuglia3, Leandro Calderón1, Diego Mazza1, Laura Lanari1, Oscar Perez1, Matias Fingermann1, Guillermo Temprano1, Guillermo Di Girolamo3, Claudio Bonel1, José Cristian Dokmetjian1
, Silvia Miranda3, Adolfo Rafael De Roodt1, Roxana Salvi2, Ivana Colaianni2, Elizabeth García2, Guillermo Bramuglia3, Leandro Calderón1, Diego Mazza1, Laura Lanari1, Oscar Perez1, Matias Fingermann1, Guillermo Temprano1, Guillermo Di Girolamo3, Claudio Bonel1, José Cristian Dokmetjian1
1Administración Nacional de Laboratorios e Institutos de Salud “Dr. Carlos G. Malbrán” (ANLIS-Malbrán), Instituto Nacional de Producción de Biológicos (INPB), Buenos Aires, Argentina
2Hospital General de Agudos Donación Francisco J. Santojanni, Buenos Aires, Argentina
3Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
Received January 21, 2025
Accepted August 27, 2025
Individual author index pages
- Guillermo Alberto Keller
- Silvia Miranda
- Adolfo Rafael De Roodt
- Roxana Salvi
- Ivana Colaianni
- Elizabeth García
- Guillermo Bramuglia
- Leandro Calderón
- Diego Mazza
- Laura Lanari
- Oscar Perez
- Matias Fingermann
- Guillermo Temprano
- Guillermo Di Girolamo
- Claudio Bonel
- José Cristian Dokmetjian
Other articles of these authors
-
Polypharmacy and Drug Interactions in the COVID-19 Pandemic
Ricardo Enrique Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto Alejandro Diez, Guido Giunti
2023, Vol. 124, Issue 4, pp. 392-412
